Corebridge Financial Inc. Has $627,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Corebridge Financial Inc. lessened its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 7.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 79,113 shares of the company’s stock after selling 5,971 shares during the period. Corebridge Financial Inc.’s holdings in Amneal Pharmaceuticals were worth $627,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of AMRX. JPMorgan Chase & Co. grew its holdings in shares of Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after buying an additional 777,568 shares in the last quarter. Barclays PLC boosted its position in Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after acquiring an additional 169,756 shares during the last quarter. State Street Corp grew its stake in shares of Amneal Pharmaceuticals by 3.8% during the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after acquiring an additional 127,753 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $520,000. Finally, Geode Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the transaction, the director now directly owns 1,808,886 shares of the company’s stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,222,590 shares of company stock valued at $43,614,546. 26.56% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AMRX shares. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays lifted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. Finally, StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $10.80.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $7.21 on Tuesday. The company has a market cap of $2.23 billion, a PE ratio of -10.60 and a beta of 1.06. The firm has a 50-day moving average of $8.33 and a 200-day moving average of $8.33. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the previous year, the business posted $0.14 EPS. Analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.